Xenetic Biosciences Inc (NASDAQ:XBIO – Get Free Report) was the recipient of a large growth in short interest in the month of October. As of October 15th, there was short interest totalling 16,800 shares, a growth of 460.0% from the September 30th total of 3,000 shares. Approximately 1.3% of the company’s shares are short sold. Based on an average daily volume of 16,800 shares, the short-interest ratio is currently 1.0 days.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a “neutral” rating on shares of Xenetic Biosciences in a report on Tuesday, August 20th.
View Our Latest Stock Report on XBIO
Xenetic Biosciences Stock Performance
Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.83) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.83). The business had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.54 million. Xenetic Biosciences had a negative net margin of 186.39% and a negative return on equity of 51.05%. On average, equities research analysts expect that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.
About Xenetic Biosciences
Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.
Read More
- Five stocks we like better than Xenetic Biosciences
- Differences Between Momentum Investing and Long Term Investing
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- How Investors Can Find the Best Cheap Dividend Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Top Biotech Stocks: Exploring Innovation Opportunities
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.